Support independent, student-run journalism.

Your support helps give staff members from all backgrounds the opportunity to conduct meaningful reporting on important issues at Stanford. All contributions are tax-deductible.

Researchers to revisit drug trials for major viruses

Stanford scientists have relaunched research on a previously shelved category of drugs, known as broad-spectrum antiviral drugs, in the hope that it will reveal information about new strategies to fight both difficult-to-combat viruses such as dengue and ebola, along with cancer.

This research, published in Nature Chemical Biology, was headed by the two senior authors of the paper, assistant professor of genetics Michael Bassik and professor of chemistry Chaitan Khosla.

The Case for Legalization

There is really no way to argue that the country’s current drug policy is successful. The war on drugs costs the U.S. taxpayers $40 billion a year, yet the United States is the still the largest illegal drug consumer in the world by far. As a percentage of our population, we lead the world in…